Abstract: A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.

Abstract: Provided are a method for supplying power to an implantable medical device and a power supply system for an implantable medical device. The power supply system supplies a constant power to the implantable medical device even when there is a movement in a body, by using a wireless power transmitter unit, a wireless power receiver unit, and a piezoelectric sensor unit stacked at the wireless power receiver unit.

Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.

Abstract: Provided is a radiation shielding device according to various embodiments. The radiation shielding device includes: a body structure forming a receiving space receiving a user's body part, wherein a through passage penetrating an inside of the body structure is formed in the body structure; a shielding unit positioned to reciprocatively move along the through passage, wherein a shielding pad configured to shield the radiation is included in a portion of the shielding unit; and a driver configured to transfer a driving force to the shielding unit to cause the shielding unit to reciprocatively move.

Abstract: The present invention relates to an antibody or antigen-binding fragment thereof against EGFRvIII (Epidermal Growth Factor Receptor Variant III), a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a composition for preventing or treating cancer, which comprises the same, a composition for diagnosing cancer, which comprises the same, and a kit for diagnosing cancer, which comprise the composition for diagnosing cancer.

Abstract: The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.

Abstract: Provided is a tongue separation device including: a body unit including a contact surface fixing a tongue; a support unit arranged at one end portion of the body unit and supporting the body unit from outside a mouth; a tooth mounting unit arranged at one surface of the support unit adjacent to a first region of the body unit, mounting the teeth in a state where the body unit is inserted into the mouth, and including an upper surface mounting upper teeth among the teeth and a lower surface mounting lower teeth among the teeth; and a tongue position checking unit including an opening formed at the support unit to check a position of the tongue from outside the mouth, wherein a first portion of the contact surface of the body unit adjacent to the one end portion of the body unit is arranged over a virtual extension surface that passes through a center of the support unit and crosses between the upper surface and the lower surface of the tooth mounting unit, and a second portion of the contact surface of the bod

Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Abstract: The purpose of the present invention is to diagnose a neurological disease such as dementia by using virtual reality, and the present invention receives a neurological disease-diagnosing problem from an external device, displays a virtual reality image through a display on the basis of the received neurological disease-diagnosing problem, and performs an examination using the virtual reality image according to user actions detected through various sensors. This process can be performed when linked with an external device such as a PC or a smart phone. Particularly, with respect to the neurological disease-diagnosing problem, the present invention includes: a first screen for introducing at least one object in a virtual reality space and hiding the same; and a second screen haying a question on the hidden object. According to the present invention, neurological disease such as dementia can be conveniently examined without inconveniencing or burdening a patient.

Abstract: A device for measuring a radiation dose according to the present invention includes a radiation exposure unit which exposes radiation, a frame unit which supports the radiation exposure unit, a measurement housing unit which is mounted on the frame unit, a scintillation unit which is mounted on the measurement housing unit and emits light due to the radiation exposed by the radiation exposure unit, an image capturing unit which captures an image of the scintillation unit, and a dose measuring unit which measures, on the basis of the captured image obtained by the image capturing unit, a dose of radiation to which the scintillation unit is exposed.

Abstract: A system for inducing respiration according to one embodiment of the present invention comprises: an imaging unit for picking a respiration image of a patient; a respiration signal conversion unit for obtaining a respiration signal of the patient by image processing, and tracking and analyzing the respiration image of the patient obtained from the imaging unit; and a respiration determination unit for determining one or more of whether the obtained respiration signal is suitable for radiation treatment, whether the obtained respiration signal is stable, and whether a matching score between the respiration signal of the patient and a guide respiration is greater than a predetermined reference value; and a respiration guide unit for providing the respiration signal of the patient, obtained from the respiration signal conversion unit, together with a stored guide signal.

Abstract: Provided is a femoral tunnel guide device including: a handle; a guide tube coupled to the handle and extending in one direction: and an offset unit extending from the guide tube and spaced apart by a predetermined distance from a virtual extension line of the guide tube in the one direction.

Abstract: Provided are a method and a device capable of: generating a first alternating current magnetic field passing through a chamber having a cell disposed therein, by using a plurality of primary coils arranged on a first plane; receiving a second alternating current magnetic field by using a plurality of secondary coils arranged on a second plane; and measuring an impedance change of a cell by using the first alternating current magnetic field and the second alternating current magnetic field.

Abstract: A biological brain age is calculated by measuring a brain cortex thickness of each region in a brain MRI image of a person to be examined, and comparing the measured brain cortex thickness with normal control group information. A device for calculating the biological brain includes an image information input unit to input an MRI brain image of a person to be examined, a brain age calculation control unit to control a biological brain age calculation operation of the person to be examined based on the MRI brain image, a brain thickness measuring unit to measure a brain cortex thickness of each region in the MRI brain image, and a brain age calculating unit to match the measured brain cortex thickness with a normal range of brain thickness of each age, and calculate a biological brain age of the person to be examined.

Abstract: The present invention relates to a method and system for providing ‘diagnosis-aiding information’, the method and system being capable of diagnosing cancer and the like of a patient by using medical imaging.

Abstract: The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.

Abstract: An embodiment of the present invention provides a radiation therapy device including: a main body; a gantry coupled to a side of the main part and rotatable relative to the main part in at least one direction; a radiation head provided on a side of the gantry to emit radiation; an image acquisition unit facing the radiation head to detect radiation emitted from the radiation head and obtain images by converting the detected radiation into electric signals; and a reference image acquisition frame provided on a side of the radiation head and including a plurality of markers formed thereon.